Literature DB >> 29959658

Prevalence of, and risk factors for, hematogenous fungal endophthalmitis in patients with Candida bloodstream infection.

Hideaki Kato1, Yukihiro Yoshimura2, Yoshihiro Suido3, Kazuo Ide4, Yoshifumi Sugiyama5, Kasumi Matsuno6, Hideaki Nakajima7.   

Abstract

PURPOSE: Endogenous fungal endophthalmitis (EFE) is a severe consequence of candidemia. The prevalence of, and risk factors for, EFE is not well studied.
METHODS: We retrospectively collected cases of patients with candidemia who had undergone ophthalmological examination between April 2011 and March 2016 in five regional hospitals. We conducted bivariate and multivariate analyses using patients' age, gender, causative Candida species, diabetes status, corticosteroid use, cancer status, neutropenia, intensive care unit admission, presence of central venous catheter (CVC), presence of shock, prior antibiotic use, 30-day mortality, and highest Sequential Organ Failure Assessment (SOFA) score. Data on sustained positive blood culture, β-D glucan, CVC removal, empirical antifungal drug used, and time to appropriate antifungal therapy were also collected if available.
RESULTS: Of 174 patients with candidemia, 35 (20.1%) were diagnosed with EFE, including 31 (17.8%) with chorioretinitis and 4 (2.3%) with vitritis. Bivariate analysis (EFE group vs. non-EFE group) found that Candida albicans candidemia (77.1 vs. 34.5%, P < 0.001), neutropenia (14.3 vs. 5.8%, P = 0.141), CVC placement (94.3 vs. 71.2%, P = 0.004), and the presence of shock (28.6 vs. 16.5%, P = 0.145) were each higher in the EFE group. Multivariate logistic regression analysis found C. albicans candidemia (adjusted odds ratio 6.48; [95% CI 2.63-15.95]) and CVC placement (7.55 [1.56-36.53]) to be significant risk factors for EFE.
CONCLUSIONS: Candida albicans is the most common causative agent for Candida EFE. Patients with candidemia and CVC placement should be closely monitored by ophthalmologists.

Entities:  

Keywords:  Bloodstream infection; Candida; Candidemia; Endophthalmitis

Mesh:

Year:  2018        PMID: 29959658     DOI: 10.1007/s15010-018-1163-z

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  27 in total

1.  Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit from infectious disease consultation.

Authors:  Dimitrios Farmakiotis; A Kyvernitakis; J J Tarrand; D P Kontoyiannis
Journal:  Clin Microbiol Infect       Date:  2014-10-12       Impact factor: 8.067

2.  Ocular manifestations of candidemia.

Authors:  Astrid M L Oude Lashof; Aniki Rothova; Jack D Sobel; Markus Ruhnke; Peter G Pappas; Claudio Viscoli; Haran T Schlamm; Iwona T Oborska; John H Rex; Bart Jan Kullberg
Journal:  Clin Infect Dis       Date:  2011-08-01       Impact factor: 9.079

3.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

4.  Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study.

Authors:  Marya D Zilberberg; Marin H Kollef; Heather Arnold; Andrew Labelle; Scott T Micek; Smita Kothari; Andrew F Shorr
Journal:  BMC Infect Dis       Date:  2010-06-03       Impact factor: 3.090

5.  Endogenous endophthalmitis among patients with candidemia.

Authors:  D W Parke; D B Jones; L O Gentry
Journal:  Ophthalmology       Date:  1982-07       Impact factor: 12.079

6.  Duration of treatment for candidemia and risk for late-onset ocular candidiasis.

Authors:  O Blennow; L Tallstedt; B Hedquist; B Gårdlund
Journal:  Infection       Date:  2012-12-02       Impact factor: 3.553

7.  Endophthalmitis in patients with disseminated fungal disease.

Authors:  Stephen S Feman; John C Nichols; Sophia M Chung; Todd A Theobald
Journal:  Trans Am Ophthalmol Soc       Date:  2002

8.  Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans.

Authors:  Seenu M Hariprasad; William F Mieler; Eric R Holz; Hua Gao; Judy E Kim; Jingduan Chi; Randall A Prince
Journal:  Arch Ophthalmol       Date:  2004-01

9.  Hematogenous candida endophthalmitis in patients receiving parenteral hyperalimentation fluids.

Authors:  D K Henderson; J E Edwards; J Z Montgomerie
Journal:  J Infect Dis       Date:  1981-05       Impact factor: 5.226

Review 10.  Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology.

Authors:  Libsen J Rodríguez-Adrián; Robert T King; Luis G Tamayo-Derat; John W Miller; Charles A Garcia; John H Rex
Journal:  Medicine (Baltimore)       Date:  2003-05       Impact factor: 1.889

View more
  14 in total

Review 1.  Essentials in Candida bloodstream infection.

Authors:  Sibylle C Mellinghoff; O A Cornely; N Jung
Journal:  Infection       Date:  2018-09-14       Impact factor: 3.553

2.  Response to Kato et al.: Prevalence of, and risk factors for, hematogenous fungal endophthalmitis in patients with Candida bloodstream infection.

Authors:  H Russell Day; Mark P Breazzano; Karen C Bloch; Edward F Cherney; Sean P Donahue; John B Bond
Journal:  Infection       Date:  2019-03-11       Impact factor: 3.553

3.  Endogenous Fungal Endophthalmitis: Causative Organisms, Treatments, and Visual Outcomes.

Authors:  Kuan-Jen Chen; Ming-Hui Sun; Yen-Po Chen; Yi-Hsing Chen; Nan-Kai Wang; Laura Liu; An-Ning Chao; Wei-Chi Wu; Yih-Shiou Hwang; Chi-Chun Lai
Journal:  J Fungi (Basel)       Date:  2022-06-16

4.  The incidence of endophthalmitis or macular involvement and the necessity of a routine ophthalmic examination in patients with candidemia.

Authors:  Takashi Ueda; Yoshio Takesue; Issei Tokimatsu; Taiga Miyazaki; Nana Nakada-Motokawa; Miki Nagao; Kazuhiko Nakajima; Hiroshige Mikamo; Yuka Yamagishi; Kei Kasahara; Shingo Yoshihara; Akira Ukimura; Koichiro Yoshida; Naomi Yoshinaga; Masaaki Izumi; Hiroshi Kakeya; Koichi Yamada; Hideki Kawamura; Kazuo Endou; Kazuaki Yamanaka; Mutsunobu Yoshioka; Kayoko Amino; Hiroki Ikeuchi; Motoi Uchino; Yoshitsugu Miyazaki
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

5.  Circumferential iris lesions in a male with cirrhosis caused by Candida dublinensis endophthalmitis.

Authors:  Suha Abu Khalaf; Ahmed Elkeeb; William Salzer; Hariharan Regunath
Journal:  IDCases       Date:  2019-09-18

6.  Teasaponin suppresses Candida albicans filamentation by reducing the level of intracellular cAMP.

Authors:  Ying Li; Mingzhu Shan; Shihui Li; Yuechen Wang; Huan Yang; Ying Chen; Bing Gu; Zuobin Zhu
Journal:  Ann Transl Med       Date:  2020-03

7.  Evaluation of Susceptibility and Innate Immune Response in C57BL/6 and BALB/c Mice During Candida albicans Endophthalmitis.

Authors:  Bruce G Rottmann; Pawan Kumar Singh; Sneha Singh; Sanjay G Revankar; Pranatharthi H Chandrasekar; Ashok Kumar
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-09-01       Impact factor: 4.799

8.  Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study.

Authors:  Carlos Mejia-Chew; Jane A O'Halloran; Margaret A Olsen; Dustin Stwalley; Ryan Kronen; Charlotte Lin; Ana S Salazar; Lindsey Larson; Kevin Hsueh; William G Powderly; Andrej Spec
Journal:  Lancet Infect Dis       Date:  2019-09-24       Impact factor: 25.071

9.  Factors associated with the development of ocular candidiasis and ocular prognosis with echinocandin therapy for candidemia.

Authors:  Daiki Sakai; Wataru Matsumiya; Sentaro Kusuhara; Makoto Nakamura
Journal:  J Ophthalmic Inflamm Infect       Date:  2021-06-14

10.  Risk factors and outcomes of patients with ocular involvement of candidemia.

Authors:  Hyo-Ju Son; Min Jae Kim; Suhwan Lee; Sungim Choi; Kyung Hwa Jung; Jiwon Jung; Yong Pil Chong; Sung-Han Kim; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Joo Yong Lee; Sang-Oh Lee
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.